Minireview: From the bench, toward the clinic: Therapeutic opportunities for cannabinoid receptor modulation

Molecular Endocrinology

Volumn 29, Issue 6, 2015, Pages 801-813

  Picone, Robert P ^a   Kendall, Debra A ^b  

^a NOVO NORDISK INC   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT;

ADDICTION; ALLOSTERISM; AMYOTROPHIC LATERAL SCLEROSIS; ANALGESIA; ARTICLE; BONE DENSITY; ENERGY BALANCE; EXCITOTOXICITY; FEEDING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RELEASE; INSULIN RESISTANCE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SECOND MESSENGER; SIGNAL TRANSDUCTION; CHEMISTRY; DISEASES; METABOLISM; TRANSLATIONAL RESEARCH;

CANNABINOID RECEPTOR MODULATORS; DISEASE; HUMANS; NEUROPROTECTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84930826663     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1062     Document Type: Article

References (122)

1. Adams R. Marihuana: Harvey Lecture, February 19, 1942. Bull NY Acad Med. 1942;18:705–730.
2. Mechoulam R, Gaoni Y. A total synthesis of dl-Delta-1-tetrahy-drocannabinol, the active constituent of hashish. J Am Chem Soc. 1965;87:3273–3275.
3. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605–613.
4. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
5. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
6. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
7. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci. 1996;16:3934-3942.
8. Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J. 1996;316(Pt 3):977-984.
9. Ueda N, Kurahashi Y, Yamamoto K, Yamamoto S, Tokunaga T. Enzymes for anandamide biosynthesis and metabolism. J Lipid Mediat Cell Signal. 1996;14:57-61.
10. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
11. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 1995;215:89-97.
12. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000;57:1045-1050.
13. Sugiura T. Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Biofactors. 2009;35:88-97.
14. Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol. 2008;20(Suppl 1):1–9.
15. Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem. 1995;270:6030-6035.
16. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J. 1997;322(Pt2):671-677.
17. Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science. 2000;289: 739-745.
18. Hurst DP, Schmeisser M, Reggio PH. Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. Chem Phys Lipids. 2013;169:46-56.
19. Mahmoud MM, Olszewska T, Liu H, et al. (4-(Bis(4-fluorophe-nyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. Mol Pharmacol. 2015; 87:197-206.
20. Shim JY, Ahn KH, Kendall DA. Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gafiy: identification of key CB1 contacts with the C-terminal helix a5 of Gai. J Biol Chem. 2013;288:32449-32465.
21. Scott CE, Abrol R, Ahn KH, Kendall DA, Goddard WA 3rd. Molecular basis for dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single and double point mutations. Protein Sci. 2013;22:101-113.
22. Zhang K, Zhang J, Gao ZG, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014; 509:115-118.
23. Tan Q, Zhu Y, Li J, et al. Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science. 2013; 341:1387-1390.
24. Rosenbaum DM, Rasmussen SG, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459:356-363.
25. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47(Suppl 1):345-358.
26. Mella-Raipán J, Hernández-Pino S, Morales-Verdejo C, Pessoa-Mahana D. 3D-QSAR/CoMFA-based structure-affinity/selectivity relationships of aminoalkylindoles in the cannabinoid CB1 and CB2 receptors. Molecules. 2014;19:2842-2861.
27. Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2014;97:55-63.
28. Wierucka-Rybak M, Wolak M, Bojanowska E. The effects of lep-tin in combination with a cannabinoid receptor 1 antagonist, AM 251, or cannabidiol on food intake and body weight in rats fed a high-fat or a free-choice high sugar diet. J Physiol Pharmacol. 2014;65:487-496.
29. Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A. 3-Substitutedpyrazole analogs of the cannabinoid type 1 (CB1) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB1, non-CB2 mechanism. J Pharmacol Exp Ther. 2012;340:433-444.
30. Lan R, Liu Q, Fan P, et al. Structure-activity relationships of pyra-zole derivatives as cannabinoid receptor antagonists. J Med Chem. 1999;42:769-776.
31. Picone RP, Khanolkar AD, Xu W, et al. (—)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol. 2005;68:1623-1635.
32. Chin CN, Murphy JW, Huffman JW, Kendall DA. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J Pharmacol Exp Ther. 1999;291:837-844.
33. Tao Q, McAllister SD, Andreassi J, et al. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol Pharmacol. 1999;55:605-613.
34. Chin CN, Lucas-Lenard J, Abadji V, Kendall DA. Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neu-rochem. 1998;70:366-373.
35. Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol. 1996;49:891-896.
36. Shire D, Calandra B, Delpech M, et al. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem. 1996;271: 6941-6946.
37. Howlett AC. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 1985;27:429-436.
38. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307-313.
39. Luttrell LM. Minireview: More than just a hammer: ligand “bias” and pharmaceutical discovery. Mol Endocrinol. 2014;28:281-294.
40. Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1999;56: 1362-1369.
41. McAllister SD, Griffin G, Satin LS, Abood ME. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther. 1999;291:618-626.
42. Ahn KH, Mahmoud MM, Samala S, Lu D, Kendall DA. Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor. J Neurochem. 2013;124:584-589.
43. Flores-Otero J, Ahn KH, Delgado-Peraza F, Mackie K, Kendall DA, Yudowski GA. Ligand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1. Nat Commun. 2014;5:4589.
44. Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. J Biol Chem. 2014;289:24845-24862.
45. Mahmoud MM, Ali HI, Ahn KH, et al. Structure-activity relationship study of indole-2-carboxamides identifies a potent allosteric modulator for the cannabinoid receptor 1 (CB1). J Med Chem. 2013;56:7965-7975.
46. Khurana L, Ali HI, Olszewska T, et al. Optimization of chemical functionalities of indole-2-carboxamides to improve allosteric parameters for the cannabinoid receptor 1 (CB1). J Med Chem. 2014;57:3040-3052.
47. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005;68:1484-1495.
48. Gamage TF, Ignatowska-Jankowska BM, Wiley JL, et al. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569. Behav Pharmacol. 2014;25:182-185.
49. Burford NT, Traynor JR, Alt A. Positive allosteric modulators of the /n-opioid receptor: a novel approach for future pain medications. Br J Pharmacol. 2015;172:277-286.
50. Horswill JG, Bali U, Shaaban S, et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol. 2007;152:805-814.
51. Navarro HA, Howard JL, Pollard GT, Carroll FI. Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 2009;156:1178-1184.
52. Pamplona FA, Ferreira J, Menezes de Lima O Jr, et al. Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci USA. 2012;109: 21134-21139.
53. Ahn KH, Mahmoud MM, Kendall DA. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem. 2012;287: 12070-12082.
54. Baillie GL, Horswill JG, Anavi-Goffer S, et al. CB1 receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol. 2013;83:322-338.
55. Piscitelli F, Ligresti A, La Regina G, et al. Indole-2-carboxamides as allosteric modulators of the cannabinoid CB1 receptor. J Med Chem. 2012;55:5627-5631.
56. Shire D, Calandra B, Bouaboula M, et al. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci. 1999;65:627-635.
57. Bolognini D, Cascio MG, Parolaro D, Pertwee RG. AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor. Br J Pharmacol. 2012;165:2561-2574.
58. Kotsikorou E, Navas F, Roche MJ, et al. The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528).JMed Chem. 2013;56:6593-6612.
59. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA. 2003;100:10529-10533.
60. Ma L, Jia J, Liu X, Bai F, Wang Q, Xiong L. Cannabinoid CB2 receptor agonist AM1241 attenuates microglial activation by modulating the activated state in N9 microglia exposed to LPS plus IFN7. Biochem Biophys Res Commun. 2015;485:92-97.
61. Hanus L, Breuer A, Tchilibon S, et al. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228-14233.
62. Pei Y, Mercier RW, Anday JK, et al. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol. 2008;15:1207-1219.
63. Nebane NM, Hurst DP, Carrasquer CA, Qiao Z, Reggio PH, Song ZH. Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor. Biochemistry. 2008;47:13811-13821.
64. Song ZH, Slowey CA, Hurst DP, Reggio PH. The difference between the CB1 and CB2 cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB2. Mol Pharmacol. 1999;56:834-840.
65. Reggio PH, Basu-Dutt S, Barnett-Norris J, et al. The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes. J Med Chem. 1998;41:5177-5187.
66. Lucchesi V, Hurst DP, Shore DM, et al. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-naphthyridin-2(1H)-one-3-carboxamides. JMed Chem. 2014;57:8777-8791.
67. Mnpotra JS, Qiao Z, Cai J, et al. Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex. J Biol Chem. 2014;289: 20259-20272.
68. Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48:443-450.
69. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.
70. Ahn KH, Mahmoud MM, Shim JY, Kendall DA. Distinct roles of /3-arrestin 1 and /3-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).JBiol Chem. 2013;288:9790-9800.
71. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K. Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol. 2012;81:250-263.
72. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563-583.
73. Onaivi ES. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. Int Rev Neurobiol. 2009;88:335-369.
74. Zhao P, Leonoudakis D, Abood ME, Beattie EC. Cannabinoid receptor activation reduces TNFa-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology. 2010;58:551-558.
75. Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069-4079.
76. Kwak S, Weiss JH. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr Opin Neurobiol. 2006; 16:281-287.
77. Oguro K, Oguro N, Kojima T, et al. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J Neurosci. 1999;19:9218-9227.
78. Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol. 1995;282:R1-R2.
79. Tsou K, Patrick SL, Walker JM. Physical withdrawal in rats tolerant to A9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol. 1995;280:R13-R15.
80. Fattore L, Cossu G, Spano MS, et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol. 2004;16: 147-158.
81. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci. 2003;17:1723-1726.
82. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401-404.
83. De Vries TJ, Shaham Y, Homberg JR, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nat Med. 2001;7:1151-1154.
84. Serra S, Carai MA, Brunetti G, et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. Eur J Pharmacol. 2001;430:369-371.
85. Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40:46-53.
86. Juan-Picó P, Fuentes E, Bermúdez-Silva FJ, et al. Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic /3-cell. Cell Calcium. 2006;39:155-162.
87. Bermudez-Silva FJ, Sanchez-Vera I, Suárez J, et al. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 2007;565:207-211.
88. Starowicz KM, Cristino L, Matias I, et al. Endocannabinoid dys-regulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring). 2008;16:553-565.
89. Malenczyk K, Jazurek M, Keimpema E, et al. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J Biol Chem. 2013;288:32685-32699.
90. Derkinderen P, Toutant M, Burgaya F, et al. Regulation of a neuronal form of focal adhesion kinase by anandamide. Science. 1996;273:1719-1722.
91. Russo P, Strazzullo P, Cappuccio FP, et al. Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab. 2007; 92:2382-2386.
92. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachi-donoyl glycerol. Br J Pharmacol. 2002;136:550-557.
93. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharma-cology (Berl). 1999;143:315-317.
94. Williams CM, Kirkham TC. Reversal of A9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav. 2002;71:333-340.
95. Wiley JL, Burston JJ, Leggett DC, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol. 2005;145:293-300.
96. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284:R345-R353.
97. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endo-cannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
98. Scheen AJ. CB1 receptor blockade and its impact on cardiometa-bolic risk factors: overview of the RIO programme with rimon-abant. J Neuroendocrinol. 2008;20(Suppl 1):139-146.
99. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-1672.
100. Di Marzo V. CB1 receptor antagonism: biological basis for metabolic effects. Drug Discov Today. 2008;13:1026–1041.
101. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adi-pocyte cells. Mol Pharmacol. 2003;63:908–914.
102. Boon MR, Kooijman S, van Dam AD, et al. Peripheral cannabi-noid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB J. 2014;28:5361–5375.
103. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115: 1298–1305.
104. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest. 2010;120:2953–2966.
105. Dhopeshwarkar A, Mackie K. CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol. 2014;86:430–437.
106. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60:255–266.
107. Yao BB, Mukherjee S, Fan Y, et al. In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol. 2006;149:145–154.
108. Brown RH Jr. Amyotrophic lateral sclerosis. Insights from genetics. Arch Neurol. 1997;54:1246–1250.
109. Nicholson SJ, Witherden AS, Hafezparast M, Martin JE, Fisher EM. Mice, the motor system, and human motor neuron pathology. Mamm Genome. 2000;11:1041–1052.
110. Ludolph AC, Meyer T, Riepe MW. The role of excitotoxicity in ALS—what is the evidence? J Neurol. 2000;247(Suppl 1):I7–I16.
111. Robberecht W. Genetics of amyotrophic lateral sclerosis. J Neu-rol. 2000;247(Suppl 6):VI/2–VI/6.
112. Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004;15:601–609.
113. Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sa-tivex(®)-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20:809–815.
114. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
115. Kim K, Moore DH, Makriyannis A, Abood ME. AM1241, a can-nabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542:100–105.
116. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007;101:87–98.
117. Kraft-Terry SD, Buch SJ, Fox HS, Gendelman HE. Acoat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron. 2009;64:133–145.
118. Thompson KA, Cherry CL, Bell JE, McLean CA. Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol. 2011;179:1623–1629.
119. Ramirez SH, Reichenbach NL, Fan S, et al. Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists. J Leukoc Biol. 2013;93:801–810.
120. Cosenza-Nashat MA, Bauman A, Zhao ML, Morgello S, Suh HS, Lee SC. Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities. Neuropathol Appl Neurobiol. 2011;37:464–483.
121. Karsak M, Cohen-Solal M, Freudenberg J, et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet. 2005;14:3389–3396.
122. Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006; 103:696–701.